These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 20454833)
1. Ascorbate/menadione-induced oxidative stress kills cancer cells that express normal or mutated forms of the oncogenic protein Bcr-Abl. An in vitro and in vivo mechanistic study. Beck R; Pedrosa RC; Dejeans N; Glorieux C; Levêque P; Gallez B; Taper H; Eeckhoudt S; Knoops L; Calderon PB; Verrax J Invest New Drugs; 2011 Oct; 29(5):891-900. PubMed ID: 20454833 [TBL] [Abstract][Full Text] [Related]
2. Oxidative stress by ascorbate/menadione association kills K562 human chronic myelogenous leukaemia cells and inhibits its tumour growth in nude mice. Verrax J; Stockis J; Tison A; Taper HS; Calderon PB Biochem Pharmacol; 2006 Sep; 72(6):671-80. PubMed ID: 16828058 [TBL] [Abstract][Full Text] [Related]
3. Hsp90 cleavage by an oxidative stress leads to its client proteins degradation and cancer cell death. Beck R; Verrax J; Gonze T; Zappone M; Pedrosa RC; Taper H; Feron O; Calderon PB Biochem Pharmacol; 2009 Feb; 77(3):375-83. PubMed ID: 19014912 [TBL] [Abstract][Full Text] [Related]
4. PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia. Gupta P; Kathawala RJ; Wei L; Wang F; Wang X; Druker BJ; Fu LW; Chen ZS Cancer Lett; 2016 Dec; 383(2):220-229. PubMed ID: 27720778 [TBL] [Abstract][Full Text] [Related]
5. Role of glycolysis inhibition and poly(ADP-ribose) polymerase activation in necrotic-like cell death caused by ascorbate/menadione-induced oxidative stress in K562 human chronic myelogenous leukemic cells. Verrax J; Vanbever S; Stockis J; Taper H; Calderon PB Int J Cancer; 2007 Mar; 120(6):1192-7. PubMed ID: 17163414 [TBL] [Abstract][Full Text] [Related]
6. Overexpression of Apg-2 increases cell proliferation and protects from oxidative damage in BaF3-BCR/ABL cells. Li C; Liu D; Yuan Y; Huang S; Shi M; Tao K; Feng W Int J Oncol; 2010 Apr; 36(4):899-904. PubMed ID: 20198334 [TBL] [Abstract][Full Text] [Related]
7. HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation. Kim SJ; Jung KH; Yan HH; Son MK; Fang Z; Ryu YL; Lee H; Lim JH; Suh JK; Kim J; Lee S; Hong S; Hong SS Oncotarget; 2015 Jan; 6(3):1507-18. PubMed ID: 25483100 [TBL] [Abstract][Full Text] [Related]
8. Preclinical development of a novel BCR-ABL T315I inhibitor against chronic myeloid leukemia. Gupta P; Zhang GN; Barbuti AM; Zhang X; Karadkhelkar N; Zhou J; Ding K; Pan J; Yoganathan S; Yang DH; Chen ZS Cancer Lett; 2020 Mar; 472():132-141. PubMed ID: 31837444 [TBL] [Abstract][Full Text] [Related]
9. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation. Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172 [TBL] [Abstract][Full Text] [Related]
10. Menadione reduction by pharmacological doses of ascorbate induces an oxidative stress that kills breast cancer cells. Beck R; Verrax J; Dejeans N; Taper H; Calderon PB Int J Toxicol; 2009; 28(1):33-42. PubMed ID: 19482829 [TBL] [Abstract][Full Text] [Related]
11. Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML). Lu T; Cao J; Zou F; Li X; Wang A; Wang W; Liang H; Liu Q; Hu C; Chen C; Hu Z; Wang W; Li L; Ge J; Shen Y; Ren T; Liu J; Xia R; Liu Q Eur J Pharmacol; 2021 Apr; 897():173944. PubMed ID: 33581133 [TBL] [Abstract][Full Text] [Related]
12. Anthelmintic niclosamide suppresses transcription of BCR-ABL fusion oncogene via disabling Sp1 and induces apoptosis in imatinib-resistant CML cells harboring T315I mutant. Jin B; Wang C; Shen Y; Pan J Cell Death Dis; 2018 Jan; 9(2):68. PubMed ID: 29358661 [TBL] [Abstract][Full Text] [Related]
13. The combination of ascorbate and menadione causes cancer cell death by oxidative stress and replicative stress. Ren X; Santhosh SM; Coppo L; Ogata FT; Lu J; Holmgren A Free Radic Biol Med; 2019 Apr; 134():350-358. PubMed ID: 30703479 [TBL] [Abstract][Full Text] [Related]
14. The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins. You L; Liu H; Huang J; Xie W; Wei J; Ye X; Qian W Oncotarget; 2017 Jan; 8(5):7777-7790. PubMed ID: 27999193 [TBL] [Abstract][Full Text] [Related]
15. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia. Yun SM; Jung KH; Kim SJ; Fang Z; Son MK; Yan HH; Lee H; Kim J; Shin S; Hong S; Hong SS Cancer Lett; 2014 Jun; 348(1-2):50-60. PubMed ID: 24657654 [TBL] [Abstract][Full Text] [Related]
16. CD-200 induces apoptosis and inhibits Bcr-Abl signaling in imatinib-resistant chronic myeloid leukemia with T315I mutation. Fang Z; Jung KH; Yan HH; Kim SJ; Son MK; Rumman M; Lee H; Kim KW; Yoo HD; Hong SS Int J Oncol; 2015 Jul; 47(1):253-61. PubMed ID: 25963192 [TBL] [Abstract][Full Text] [Related]